P14.108 Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma

BACKGROUND: The use of alkylating chemotherapy versus bevacizumab for recurrent glioblastoma remains controversial. Here we tested the hypothesis that the activity of alkylators, but not that of bevacizumab, would be associated with the O(6)-methylguanine DNA methyltransferase (MGMT) promoter methyl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Seystahl, K, Hentschel, B, Loew, S, Gramatzki, D, Felsberg, J, Herrlinger, U, Westphal, M, Schackert, G, Thon, N, Schlegel, U, Tatagiba, M, Pietsch, T, Reifenberger, G, Löffler, M, Wick, W, Weller, M
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Poster Presentations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795773/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.343
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars